Recent advances in melanoma research

Journal of Dermatological Science

Volumn 26, Issue 1, 2001, Pages 1-13

  Saida, Toshiaki ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene alterations; Malignant melanoma; Molecular events; New treatment; Pathogenesis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CADHERIN; CARMUSTINE; CELL ADHESION MOLECULE; CISPLATIN; DACARBAZINE; INTEGRIN; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; PROTEIN P53; TEMOZOLOMIDE;

CANCER INVASION; EXON; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC LINKAGE; HUMAN; MELANOCYTE; MELANOMA; MUTATION; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ULTRAVIOLET IRRADIATION;

CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 9; GENES, P16; HUMANS; MELANOMA; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0035040353     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(01)00085-8     Document Type: Review

References (89)

1. Molecular biology of human melanoma development and progression
2. Genes involved in melanoma: an overview of INK4a and other loci
3. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors
4. Molecular events in melanoma development and progression
5. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation
6. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22
7. Familial melanoma: CDKN2A and beyond
8. Homozygous deletions within human chromosome band 9p21 in melanoma
9. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanoma and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s)
10. A cell cycle regulator potentially involved in genesis of many tumor types
11. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
12. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
13. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene
14. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
15. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi
16. INK4a binding domain of CDK4 in familial melanoma
17. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A(p16/INK4a) gene
18. Germline p16 mutation in familial melanoma
19. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations
20. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus
21. INK4 proteins in cutaneous malignant melanoma
22. The concept of de novo origin of cutaneous malignant melanoma
23. Relationship between mole and malignant melanoma
24. A novel p16INK4a transcript
25. Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines
26. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus syndrome to chromosome 1p
27. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi
28. Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases
29. Chromosomal gains and losses in primary cutaneous melanomas deleted by comparative genomic hybridization
30. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancers
31. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma
32. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6
33. AIM1, a novel non-lens member of the ßγ-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma
34. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype
35. N-ras mutations in human cutaneous melanoma from sun-exposed body sites
36. RAS mutations in human melanoma: a marker of malignant progression
37. Expression of acquired N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-ß
38. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma
39. Absence of p53 gene mutations in cutaneous melanoma
40. Regulation of MelCAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes
41. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion
42. 3 integrin in melanoma and nevi
43. 3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma
44. Shifts in cadherin profiles between human normal melanocytes and melanomas
45. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression
46. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors
47. Frequent nuclear/cytoplasmic location of ß-cadherin without exon 3 mutations in malignant melanoma
48. Stabilization of ß-catenin by genetic defects in melanoma cell lines
49. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
50. Matrix metalloproteinases in human melanoma
51. Activation mechanisms of matrix metalloproteinases
52. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1
53. Melanoma-mediated dissolution of extracellular matrix: contribution of urokionase-dependent and metalloproteinase-dependent proteolytic pathways
54. The 92-kD gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells
55. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
56. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloproteinase docking to invadopodia is required for cell invasion
57. Expression and activation of matrix metalloproteinase-2(MMP-2) and its colocalization with membrane-type matrix metalloproteinase 1(MT1-MMP) correlate with melanoma progression
58. 3
59. 3 correlates with activation of membrane-type matrix metalloproteinase-1(MT1-MMP) and matrix metalloproteinase-2(MMP-2) in human melanoma cells in vitro and in vivo
60. 3 and matrix metalloproteinase-2(MMP-2) coincides with MMP-2 activation: correlation with melanoma progression
61. Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provide a mechanism for CD44-mediated tumor invasion
62. Moesin and CD44 expression in cutaneous melanocytic tumors
63. Increased synthesis of hyaluronate enhances motility of human melanoma cells
64. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant Melanomas
65. Prognostic value of tumor vascularity in primary melanoma
66. Human malignant melanoma cells release a factor that inhibits the expression of smooth muscle α-actin
67. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry
68. Gene amplifications characterize acral melanoma and permit the deletion of occult tumor cells in the surrounding skin
69. Malignant melanoma on the sole: how to detect the early lesions efficiently
70. A new American Joint Committee on Cancer Staging System for cutaneous melanoma
71. What is the most promising strategy for the treatment of metastasizing melanoma?
72. Systemic chemotherapy for the treatment of metastatic melanoma
73. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
74. Combination of chemotherapy with interleukin-2 and interferon α for the treatment of metastatic melanoma
75. Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-α +/- interleukin-2 in patients with metastatic melanoma
76. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced melanoma patients
77. Sequential chemoimmunotherapy with cisplatin, interferon-ß and interleukin-2 inhibits the growth of B16-F1 melanoma in synergetic mice
78. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity
79. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
80. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
81. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases
82. Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines
83. Molecular classification of cutaneous malignant melanoma by gene expression profiling